You are here: Industry Insights > china

News List

“Conditional Approval” Contributing a Great Share in the New Drug Marketing Acceleration in China Erxiao
September 12, 2018
Several blockbuster drugs such as 9-valent HPV vaccine and Pyrotinib Maleate Tablets have recently been fast approved for marketing in China...
Bio processing and manufacturing league table ranks US top and China bottom cphi-online
September 12, 2018
US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.
China’s self-developed heart stent gets recognition worldwide biospectrum
September 12, 2018
Results showed that the safety and clinical efficacy of this stent could rival the Xience stent, one of the world's leading drug-eluting stents.
Chi-Med’s fruquintinib gets approval for colorectal cancer in China pharmaceutical-technology
September 11, 2018
Hutchison China MediTech (Chi-Med) has secured approval from the National Medical Products Administration of China (NMPA) for the use of fruquintinib capsules to treat metastatic colorectal cancer (CRC).
Eisai's Lenvima gets nod in China for liver cancer treatment biospectrumasia
September 07, 2018
HBV is considered to be a negative predictor of tumor response to existing drug therapies.
Thermo Fisher releases GeneArt products in China biospectrumasia
September 05, 2018
GeneArt products will help customers accelerate the path from planning experiments to executing them in the lab.
China accepts first application for Humira biosimilar biospectrumasia
September 05, 2018
Bio-Thera Solutions is developing several additional proposed biosimilars, including a biosimilar version of Avastin, which is currently being evaluated in a global Phase III clinical trial
PARP inhibitors arrive in China via new priority review pathway pharmaceutical-technology
September 04, 2018
On August 24, AstraZeneca’s Lynparza (olaparib) was approved in China for maintenance therapy of platinum-sensitive recurrent ovarian cancer.
Illumina receives 1st approval in China for its MiSeqDx sequencing system fiercebiotech
August 30, 2018
With a certificate from the China National Drug Administration, Illumina has begun encouraging more clinical laboratories to choose the MiSeqDx system to develop new clinical assays.
BeiGene Announces Acceptance of its First NDA for Zanubrutinib biospectrumasia
August 30, 2018
Zanubrutinib is being studied in several clinical trials as part of a broad development program and was recently granted Fast Track Designation by the US FDA

Previous page 1 2 3 4 5 6 7 8 9 10 ... 38 39 Next page